Latest issue of Clinical laboratory
January 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
Azenta unveils networked 2D-coded tube readers
, /in Product News /by panglobalAzenta Life Sciences has launched two next-generation camera-based tube readers designed to enhance laboratory workflows and support cold-chain sample processing. The Mirage Connect and Cube Connect devices, marketed under the Ziath brand portfolio, feature fully integrated networking capabilities and passive cryoprotection for frozen sample management.
AMSBIO introduces SoluLyse for bacterial protein extraction
, /in Product News /by panglobalAMSBIO has introduced SoluLyse, a bacterial protein extraction reagent designed to provide efficient extraction of soluble proteins from bacterial cells without requiring sonication or freeze-thaw methods.
Vapourtec launches free flow chemistry teaching manual
, /in Product News /by panglobalVapourtec has released a comprehensive flow chemistry teaching manual for undergraduate chemistry education, developed in collaboration with Dr Nicholas Leadbeater and the New Synthetic Methods Group at the University of Connecticut.
Nuclera installs eProtein Discovery systems at Taiwan universities
, /in E-News /by panglobalCambridge-based biotechnology company Nuclera has completed its first commercial installations in Asia, deploying eProtein Discovery systems at two leading Taiwanese universities. The National Taiwan University and National Cheng Kung University now have access to the benchtop protein production technology, marking a significant milestone in the company’s global expansion.
Revvity to acquire ACD/Labs in research informatics expansion
, /in E-News /by panglobalRevvity has entered into a definitive agreement to acquire ACD/Labs, a global provider of scientific software solutions supporting analytical characterisation and molecular design across pharmaceutical and material sciences sectors.
CHITOSE and FUJIFILM Biosciences announce strategic alliance for biopharmaceutical production
, /in E-News /by panglobalChitose Laboratory Corp. and FUJIFILM Biosciences Inc. have formed a strategic alliance to advance biopharmaceutical manufacturing by combining CHO-MK cell line technology with GMP-manufactured culture media. The collaboration aims to enhance production efficiency and support the development of therapeutic solutions for the global pharmaceutical industry.
ProteoNic licenses vector technology for antibody manufacturing consortium
, /in E-News /by panglobalProteoNic BV has announced that Ginkgo Bioworks has licensed its proprietary 2G UNic vector technology for a $22.2 million project funded by the Biomedical Advanced Research and Development Authority (BARDA). The initiative aims to enhance domestic biomanufacturing capabilities for monoclonal antibodies targeting filovirus infections, including Ebola and Sudan Virus.
ProBioGen partners with Spica Therapeutics for ST101 development
, /in E-News /by panglobalProBioGen has announced a collaboration with Spica Therapeutics to perform cell line development for ST101, a first-in-class monoclonal antibody designed to selectively deplete immunosuppressive CD163+ tumour-associated macrophages in oncology applications.
FineLine Technologies acquires Digi-Trax healthcare labelling specialist
, /in E-News /by panglobalFineLine Technologies has announced the acquisition of Digi-Trax Corp., a provider of healthcare labelling and identification solutions specialising in blood collection and cellular therapy applications. The deal, announced on 10 December 2025, marks FineLine’s strategic expansion into the healthcare sector and will see Digi-Trax operate as the company’s new Healthcare Division.
EVerZom signs research collaboration with GENFIT to advance exosome therapy
, /in E-News /by panglobalEVerZom, a French biotechnology company developing exosome-based therapies for regenerative medicine, has entered into a research collaboration with GENFIT, a biopharmaceutical company specialising in rare liver diseases. The partnership will evaluate EViv, EVerZom’s second proprietary investigational drug candidate, which has been developed to treat acute-on-chronic liver failure (ACLF).